Noxopharm Limited 24 Consolidated Note 2022 $ 2021 $ Revenue Revenue and other income 4 5,475,590 5,797,723 Net (loss)/gain on investment at fair value through profit and loss 10 (8,857,384) 8,774,212 Expenses Corporate administration expenses 5 (1,769,101) (1,722,626) Research and development expenses (7,777,415) (12,560,987) Depreciation and amortisation expenses (261,513) (261,723) Consulting, employee & director expenses 5 (5,399,652) (5,656,445) Finance costs 5 (77,335) (2,198,505) Share of loss of Associate (to 29 June 2021) - (1,040,874) Fair value movement in derivative liability - (477,524) Loss before income tax expense (18,666,810) (9,346,749) Income tax expense 6 - - Loss after income tax expense for the year attributable to the owners of Noxopharm Limited (18,666,810) (9,346,749) Other comprehensive income for the year, net of tax - - Total comprehensive income for the year attributable to the owners of Noxopharm Limited (18,666,810) (9,346,749) Cents Cents Basic earnings per share 25 (6.41) (3.54) Diluted earnings per share 25 (6.41) (3.54) Statement of Profit or Loss and Other Comprehensive Income For the year ended 30 June 2022
RkJQdWJsaXNoZXIy MjE2NDg3